Just a few months ago some bold investors picked up shares in various companies, at the bottom of the markets’ recent rocket-like recovery, many for 20-30% gains.
While those results are nothing to sneeze at, what I’m looking at is potentially much bigger. Plus, most of the recovery trades are now long gone and the market seems precariously overvalued, but, regardless of the direction that the wider economic recovery takes, biotechs are poised to continue to lead the way.
Endari®, which has already hit over $20 million in sales, and growing, in just 3 years of FDA approval, is currently used to treat Sickle Cell Anemia. However, Endari is showing very promising phase 2 results for Diverticulosis, a potentially massive market with limited competition.
Endari®, which has already hit over $20 million in sales, and growing, in just 3 years of FDA approval, is currently used to treat Sickle Cell Anemia. However, Endari is showing very promising phase 2 results for Diverticulosis, a potentially massive market with limited competition.
Considering those factors, and more, its stock should score highly on value, growth and quality.
With the success of Endari® for treating Sickle Cell and tests showing promise for Diverticulosis, EMMA is poised for future success and should be able to create significant value for shareholders, who take a position while the company is finishing their audits.
The company is well funded, continues to grow revenues and has announced several new partners in multiple countries to expand its products footprint. There will, undoubtedly, be updates on these ventures, more Phase 3 Diverticulosis test news, which is a disease that afflicts 60% of all adults over the age of 60.
Our editors have been buying shares, and we plan to sell them when the company relists on NASDAQ, or the price action is such that it makes sense to exit. This trade should be great with the overcharged market, and we believe it makes sense for a longer-term hold at these levels
24/7 Market News
Editor